Eloxx Pharmaceuticals

ELOX Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

Exaluren nmADPKD enrollment done2027Exaluren nmADPKD enrollment done, 2027, routine
Exaluren NMAS toplinemid-2027Exaluren NMAS topline, mid-2027, thesis-defining
Exaluren NMAS toplineby mid-2027Exaluren NMAS topline, by mid-2027, thesis-defining
Exaluren nmADPKD Ph2 toplinemid-2028Exaluren nmADPKD Ph2 topline, mid-2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

exaluren

Small Molecule Target: ribosome, COL4A3, COL4A4, COL4A5, Collagen IV, PKD1, PKD2, polycystin-1, polycystin-2

Alport Syndrome Phase 2 subcutaneous NCT07523581
Autosomal Dominant Polycystic Kidney Disease Preclinical

ZKN-013

Small Molecule Target: ribosome, COL7A1, LAMB3

Recessive Dystrophic Epidermolysis Bullosa Phase 1 oral Almirall
Junctional Epidermolysis Bullosa Phase 1 oral Almirall

Biotech Distilled coverage (3)

2026-09-11 UPDATE: Eloxx Pharmaceuticals (ELOX) - The Trial Starts, and So Does the Exit Door 🔒 Paid
2026-08-12 UPDATE: Eloxx Pharmaceuticals (ELOX) - The Quarter Where the Money Showed Up and the Trial Didn’t 🔒 Paid
2026-06-18 Eloxx Pharmaceuticals (ELOX) — Scientific Deep Dive for Exaluren and the Ribosomal Readthrough Pipeline 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.